1. Home
  2. PKBK vs MDWD Comparison

PKBK vs MDWD Comparison

Compare PKBK & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parke Bancorp Inc.

PKBK

Parke Bancorp Inc.

HOLD

Current Price

$24.85

Market Cap

269.2M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.72

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PKBK
MDWD
Founded
1999
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.2M
238.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PKBK
MDWD
Price
$24.85
$18.72
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
39.5K
82.4K
Earning Date
01-23-2026
11-20-2025
Dividend Yield
2.90%
N/A
EPS Growth
21.56
N/A
EPS
2.83
N/A
Revenue
$71,766,000.00
$20,932,000.00
Revenue This Year
N/A
$15.89
Revenue Next Year
N/A
$25.33
P/E Ratio
$8.76
N/A
Revenue Growth
13.64
6.15
52 Week Low
$16.94
$14.14
52 Week High
$25.77
$22.51

Technical Indicators

Market Signals
Indicator
PKBK
MDWD
Relative Strength Index (RSI) 64.95 57.39
Support Level $24.56 $18.55
Resistance Level $25.70 $18.96
Average True Range (ATR) 0.46 0.53
MACD -0.12 0.01
Stochastic Oscillator 54.77 49.21

Price Performance

Historical Comparison
PKBK
MDWD

About PKBK Parke Bancorp Inc.

Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: